Distinguished in Rosacea

Dr. Walter Nahm

Dermatology
Walter K Nahm MD PhD Inc.
7695 Cardinal Ct Ste 200, 
San Diego, CA 
Distinguished in Rosacea
Walter K Nahm MD PhD Inc.
7695 Cardinal Ct Ste 200, 
San Diego, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Walter Nahm is a Dermatologist in San Diego, California. Dr. Nahm is rated as a Distinguished provider by MediFind in the treatment of Rosacea. His top areas of expertise are Rosacea, Actinic Keratosis, Eschar, and Necrotizing Granuloma.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Rosacea.

Specialties
Dermatology
Licenses
Dermatology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Walter K Nahm MD PhD Inc.
7695 Cardinal Ct Ste 200, San Diego, CA 92123
Call: 858-278-8835

Additional Areas of Focus

Dr. Nahm has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
Enrollment Status: Terminated
Publish Date: August 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 10 Less Clinical Trials

11 Total Publications

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 30, 2025
View All 11 Publications
Similar Doctors
Distinguished in Rosacea
Dr. Richard Gallo
Dermatology
Distinguished in Rosacea
Dr. Richard Gallo
Dermatology

UC San Diego Student Health SVC Pharmacy

9500 Gilman Dr, 
La Jolla, CA 
 (7.3 miles away)
619-543-5580
Languages Spoken:
English
See accepted insurances

Richard Gallo is a Dermatologist in La Jolla, California. Dr. Gallo is rated as a Distinguished provider by MediFind in the treatment of Rosacea. His top areas of expertise are Rosacea, Atopic Dermatitis, Acne, and Pustules.

Distinguished in Rosacea
Dr. Neal Bhatia
Dermatology
Distinguished in Rosacea
Dr. Neal Bhatia
Dermatology

TCR Medical Corp.

9025 Balboa Ave Ste 105, 
San Diego, CA 
 (2.5 miles away)
858-571-6800
Languages Spoken:
English
See accepted insurances

Neal Bhatia is a Dermatologist in San Diego, California. Dr. Bhatia is rated as an Advanced provider by MediFind in the treatment of Rosacea. His top areas of expertise are Rosacea, Actinic Keratosis, Atopic Dermatitis, and Acne.

Distinguished in Rosacea
Dr. Tissa Hata
Dermatology
Distinguished in Rosacea
Dr. Tissa Hata
Dermatology

Kevin W. Broder M. D. Incorporated

8899 University Center Ln Ste 350, 
San Diego, CA 
 (6.8 miles away)
858-657-8322
Languages Spoken:
English
See accepted insurances

Tissa Hata is a Dermatologist in San Diego, California. Dr. Hata is rated as a Distinguished provider by MediFind in the treatment of Rosacea. Her top areas of expertise are Atopic Dermatitis, Actinic Keratosis, Rosacea, and Sunburn.

VIEW MORE ROSACEA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nahm's expertise for a condition
ConditionClose
    • Distinguished
    • Actinic Keratosis
      Dr. Nahm is
      Distinguished
      . Learn about Actinic Keratosis.
      See more Actinic Keratosis experts
    • Epidermoid Cyst
      Dr. Nahm is
      Distinguished
      . Learn about Epidermoid Cyst.
      See more Epidermoid Cyst experts
    • Eschar
      Dr. Nahm is
      Distinguished
      . Learn about Eschar.
      See more Eschar experts
    • Granulomatous Hypophysitis
      Dr. Nahm is
      Distinguished
      . Learn about Granulomatous Hypophysitis.
      See more Granulomatous Hypophysitis experts
    • Lymphomatoid Granulomatosis
      Dr. Nahm is
      Distinguished
      . Learn about Lymphomatoid Granulomatosis.
      See more Lymphomatoid Granulomatosis experts
    • Necrotizing Granuloma
      Dr. Nahm is
      Distinguished
      . Learn about Necrotizing Granuloma.
      See more Necrotizing Granuloma experts
    View All 9 Distinguished Conditions
    • Advanced
    • Acrogeria, Gottron Type
      Dr. Nahm is
      Advanced
      . Learn about Acrogeria, Gottron Type.
      See more Acrogeria, Gottron Type experts
    • Alopecia Areata
      Dr. Nahm is
      Advanced
      . Learn about Alopecia Areata.
      See more Alopecia Areata experts
    • Athlete's Foot
      Dr. Nahm is
      Advanced
      . Learn about Athlete's Foot.
      See more Athlete's Foot experts
    • Autosomal Recessive Hypotrichosis
      Dr. Nahm is
      Advanced
      . Learn about Autosomal Recessive Hypotrichosis.
      See more Autosomal Recessive Hypotrichosis experts
    • Bazex Syndrome
      Dr. Nahm is
      Advanced
      . Learn about Bazex Syndrome.
      See more Bazex Syndrome experts
    • Comedones
      Dr. Nahm is
      Advanced
      . Learn about Comedones.
      See more Comedones experts
    View All 41 Advanced Conditions
    • Experienced
    • Acanthosis Nigricans
      Dr. Nahm is
      Experienced
      . Learn about Acanthosis Nigricans.
      See more Acanthosis Nigricans experts
    • Atopic Dermatitis
      Dr. Nahm is
      Experienced
      . Learn about Atopic Dermatitis.
      See more Atopic Dermatitis experts
    • Autoerythrocyte Sensitivity
      Dr. Nahm is
      Experienced
      . Learn about Autoerythrocyte Sensitivity.
      See more Autoerythrocyte Sensitivity experts
    • Basal Cell Skin Cancer
      Dr. Nahm is
      Experienced
      . Learn about Basal Cell Skin Cancer.
      See more Basal Cell Skin Cancer experts
    • Boils
      Dr. Nahm is
      Experienced
      . Learn about Boils.
      See more Boils experts
    • Bullae
      Dr. Nahm is
      Experienced
      . Learn about Bullae.
      See more Bullae experts
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.